Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of CE1145 in hereditary angioedema
2005-003139-38Phase 3
- Sponsor
- CSL Behring
- Start
- Feb 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Human C1-esterase inhibitor in hereditary angioedema (HAE), sponsored by CSL Behring. Primary endpoint: Time to onset of relief of symptoms.
02
Drugs
Human C1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2005-003139-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003139-38.